Eli Lilly And Company ((LLY)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Eli Lilly and Company, in collaboration with AstraZeneca, is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer – SUNRAY-02’. The study aims to evaluate the effectiveness of olomorasib combined with standard immunotherapy compared to placebo in treating KRAS G12C-mutant non-small cell lung cancer (NSCLC), a significant step in addressing a challenging cancer mutation.
Intervention/Treatment: The study tests olomorasib, an oral drug, in combination with pembrolizumab or durvalumab, both administered intravenously. These combinations are compared against a placebo to determine their efficacy in treating NSCLC.
Study Design: This interventional study is randomized and double-blind, meaning neither participants nor investigators know who receives the treatment or placebo. It uses a parallel assignment model with the primary purpose of treatment, focusing on assessing the safety and efficacy of the drug combinations.
Study Timeline: The study began on March 27, 2025, with its latest update submitted on July 7, 2025. The timeline is crucial for tracking progress and anticipating results, which could influence treatment options and market dynamics.
Market Implications: The study’s outcome could significantly impact Eli Lilly and AstraZeneca’s stock performance and investor sentiment, especially if olomorasib proves effective. Success could position these companies as leaders in the NSCLC treatment market, intensifying competition with other pharmaceutical firms targeting similar cancer mutations.
The study is ongoing, with further details available on the ClinicalTrials portal.